To include your compound in the COVID-19 Resource Center, submit it here.

Ficlatuzumab: Phase Ib data

An open-label, dose-escalation, Asian Phase Ib trial in 12 evaluable patients with unresectable NSCLC who received 20 mg/kg IV ficlatuzumab

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE